MASH describes an inflammatory liver disease triggered by metabolic dysregulation and fat accumulation within the liver. While MASLD incidence has surged globally in parallel with obesity and type 2 diabetes pandemics, the mechanistic details about why the disease progresses differently in males and females have remained elusive. This latest research reveals a distinctive role for GPR110, a G-protein-coupled receptor (GPCR) expressed selectively in hepatocytes, that differentially influences the disease course in male and female subjects.

The team employed hepatocyte-specific Gpr110 knockout mouse models to dissect the receptor’s role in MASH. Strikingly, female mice lacking Gpr110 in their liver cells exhibited marked protection against MASH. This sex-dependent protective effect was absent in male mice, suggesting an intrinsic biological divergence modulated by GPR110’s signaling. This discovery challenges the conventional one-size-fits-all approach to liver metabolic disease and calls attention to the importance of sex as a biological variable in future research and drug development.

Complementing their experimental model, the researchers analyzed genetic data identifying a variant of the GPR110 gene, known as rs937057 (a thymine to cytosine substitution), significantly associated with a higher prevalence of metabolic dysfunction-associated steatotic liver disease in women. This variant highlights a genetic predisposition component modulated through GPR110, pointing to the receptor’s potential as both a biomarker and a target for precision medicine in female populations.

Delving deeper into the molecular mechanisms, the investigation uncovered that the hepato-protective phenotype in female mice hinges on the presence and functional integrity of hepatic estrogen receptor alpha (Esr1). When Esr1 expression was knocked down in the liver, the protective benefits conferred by Gpr110 deletion were nullified. This indicates that GPR110 operates through modulating the estrogen receptor signaling axis, tightly linking metabolic dysfunction in the liver with hormonal regulation that differs between sexes.

At the biochemical level, the researchers demonstrated that GPR110 couples explicitly to the Gα_s protein subunit, which activates protein kinase A (PKA). This cascade leads to phosphorylation of the nuclear factor of activated T cells 2 (NFAT2), a transcription factor crucial in various cellular processes. Phosphorylated NFAT2 is hindered from translocating into the nucleus, thereby suppressing its capacity to drive Esr1 gene transcription in hepatocytes. Consequently, GPR110 activation results in a downregulation of estrogen receptor alpha signaling, diminishing the liver’s estrogen sensitivity and exacerbating MASH pathogenesis predominantly in females.

This elegant mechanistic insight not only clarifies GPR110’s role in hepatic metabolic regulation but also explains the observed sex differences in MASH progression. Women’s livers appear more sensitive to estrogen receptor signaling, which normally confers a protective effect. GPR110, by attenuating this pathway, inadvertently promotes disease development. The absence of this signaling in males suggests alternate pathogenic routes underlying their disease phenotype, further underscoring the complexity of metabolic liver disease.

The translational implications of these findings are profound. Therapeutic strategies aimed at inhibiting GPR110 function present a novel avenue for sex-specific intervention in MASH. Targeting this receptor selectively in hepatocytes could restore estrogen receptor alpha activity in women, thereby mitigating the progression of liver inflammation and fibrosis characteristic of MASH. Such approaches could revolutionize the currently limited treatment landscape for this increasingly prevalent disease.

Moreover, genetic screening for the rs937057 variant might allow identification of high-risk female individuals for early intervention and personalized treatment plans. Integration of genotype-guided therapy could enhance clinical outcomes and reduce the burden of advanced liver disease. The study also invites further research into whether modulation of GPR110 signaling can synergize with other therapeutic agents to amplify hepatoprotective effects.

Beyond its immediate clinical implications, this work sets a precedent for investigating other GPCRs in the liver and other metabolic organs. GPR110 exemplifies how sex hormones interact intricately with metabolic pathways, influencing disease susceptibility and progression. Investigating similar receptors and their downstream signaling networks can unveil additional molecular targets vital for combating metabolic disorders that display sex biases.

To ensure clinical relevance, future studies will need to explore GPR110’s role in human liver tissue and examine the receptor’s expression and function across diverse populations and metabolic conditions. Longitudinal studies could elucidate the receptor’s involvement in disease progression and response to lifestyle or pharmacological interventions. Additionally, the safety and efficacy of GPR110 antagonists in preclinical models must be rigorously evaluated before contemplating clinical trials.

In summary, this pivotal research elucidates the liver-specific G-protein-coupled receptor GPR110 as a key determinant of sex-specific differences in metabolic dysfunction-associated steatohepatitis. By selectively modulating hepatic estrogen receptor alpha signaling through a novel Gα_s–PKA–NFAT2 axis, GPR110 influences the susceptibility and severity of MASH primarily in females. These insights expand our understanding of the molecular underpinnings of liver metabolic diseases and pave the way for sex-specific therapeutic innovations addressing this growing global health challenge.

As metabolic liver diseases continue to afflict millions worldwide, advancements such as those presented in this study are essential. They not only decode complex biological interactions but also translate into tangible clinical benefits through precision medicine. The sex disparity unveiled here serves as a reminder that nuanced, mechanistically guided approaches are crucial in developing effective treatments tailored to individual biological contexts.

Ongoing efforts to target GPR110 could revolutionize the management of MASH and potentially other metabolic conditions with sex-linked disparities. Such breakthroughs herald a new era of personalized hepatology, emphasizing hormone receptor crosstalk and receptor pharmacology as frontlines in combating metabolic syndrome’s hepatic manifestations. This study thus represents a beacon of hope amid the escalating global burden of liver disease.

Subject of Research: Sex-specific mechanisms in metabolic dysfunction-associated steatohepatitis involving hepatic GPR110 and estrogen receptor alpha signaling.

Article Title: Hepatic GPR110 contributes to sex disparity in the development of MASH through oestrogen receptor α-dependent signalling.

Article References:
Yang, F., Wang, W., Qiu, F. et al. Hepatic GPR110 contributes to sex disparity in the development of MASH through oestrogen receptor α-dependent signalling. Nat Metab (2026). https://doi.org/10.1038/s42255-025-01436-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01436-1

A significant aspect of MASH is the disruption of endoplasmic reticulum (ER) homeostasis, a crucial cellular compartment responsible for protein synthesis, folding, and lipid metabolism. The ER plays a pivotal role in calcium ion (Ca²⁺) storage and signaling, which is fundamental to its operational integrity. When the balance of folded and unfolded proteins is disturbed—often due to genetic factors, excess nutritional intake, or environmental stressors—the ER responds through a complex series of mechanisms known as ER stress. Chronic ER stress has been implicated in the pathophysiology of numerous metabolic disorders, including MASH. Recent investigations have begun to elucidate the significant role of sarco/ER calcium ATPase (SERCA2), a critical protein that mediates calcium transport within the ER, in maintaining this delicate balance. Dysfunction of SERCA2 has been linked to heightened ER stress, providing a possible nexus between calcium dysregulation and the advancement of MASH.

Delving into the genetic aspects of MASH, researchers have focused their attention on the NACHT and WD repeat domain-containing protein 1 (Nwd1) gene, known to be pivotal in various cellular functions, including signal transduction and ER dynamics. This gene is expressed in significant levels in both hepatic and central nervous tissues, yet its role in the context of liver pathogenesis associated with MASH has remained obscure until recently. One of the most intriguing revelations surrounding Nwd1 is its potential interaction with SERCA2, hinting at a collaborative relationship that might regulate ER function and overall liver homeostasis.

A recent publication in the journal Communications Biology has shed light on this interaction, as a team, led by Professor Shin-ichi Sakakibara from Waseda University in Japan, has undertaken a comprehensive study exploring the physiological implications of Nwd1 deletion in the context of MASH. The publication is significant not only for its exploration of Nwd1’s role but also for its broader implications in understanding the multifaceted nature of liver diseases, particularly in how genetic factors may influence the risk and progression of metabolic disorders.

Employing CRISPR-Cas9 genome editing technology, the research team created a knockout model devoid of Nwd1 (Nwd1^−/− mice). These genetically modified mice were then subjected to extensive evaluation to ascertain the implications of Nwd1 deficiency on liver functionality and cellular processes. The findings were compelling; the absence of Nwd1 led to pronounced liver abnormalities characterized by severe lipid accumulation, fibrosis, and a marked increase in ER stress—phenomena that strikingly mirror the features observed in human MASH patients. Moreover, the study also found an alarming uptick in pyroptosis, a form of inflammatory cell death characterized by the activation of caspase-1, indicating a stark enhancement of hepatic inflammation and resultant tissue damage.

The data presented by Dr. Seiya Yamada, the first co-author of the study, provided significant insights into the regulatory role of Nwd1. The research disclosed that Nwd1 operates not in isolation but as a crucial regulator of ER stress mechanisms that are integral to maintaining calcium homeostasis within the liver. The deficiency of Nwd1 severely hampered SERCA2 activity, resulting in diminished Ca²⁺ storage capabilities of the ER, which in turn exacerbated the cellular stress response and facilitated lipid droplet accumulation—a hallmark of MASH.

The implications of these findings reach far beyond just theoretical significance. They suggest that targeting ER stress pathways may provide a viable strategy for developing new, much-needed therapies aimed at treating MASH. As Dr. Yamada pointed out, the mechanisms driving MASH are still not fully understood, and current therapeutic offerings are limited to a single approved drug. This gap in effective treatment options amplifies the urgency for research focused on identifying molecular targets that can be manipulated to ameliorate MASH progression.

In summary, the work led by Dr. Sakakibara and his colleagues presents a pivotal contribution to the understanding of MASH pathogenesis. By conceptualizing Nwd1 as a critical regulator within the ER calcium transport pathway, the study opens avenues for future research aimed at unraveling the complexities of liver diseases grounded in metabolic dysfunction. Importantly, as the prevalence of MASH continues to rise globally, advances in our understanding of its mechanistic underpinnings could lead to innovative therapeutic approaches that may ultimately reduce the burden of this disease.

In conclusion, the investigation into the role of Nwd1 in MASH represents a significant advance in our understanding of liver diseases and highlights the potential of gene-targeted therapies. The revelations from this study underscore the importance of continued exploration of molecular pathways involved in metabolic disorders. As researchers continue to piece together the intricate puzzle of MASH, the hope is that such insights will lead to effective treatment strategies that can transform the landscape of liver disease management and improve patient outcomes across diverse populations.

Subject of Research: Animals
Article Title: Induction of MASH-like pathogenesis in the Nwd1−/− mouse liver
News Publication Date: 11-Mar-2025
Web References: https://doi.org/10.1038/s42003-025-07717-5
References: Communications Biology
Image Credits: Professor Shin-ichi Sakakibara from Waseda University, Japan

Keywords: Metabolic dysfunction, liver disease, steatohepatitis, ER stress, Nwd1, SERCA2, therapeutic targets.